All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The FDA has decided not to grant approval to quizartinib for the treatment of patients with FLT3-internal tandem duplication-positive relapsed/refractory (R/R) acute myeloid leukemia, as results of a trial failed to show that the benefits of the treatment outweigh the risks.
At an Oncolytic Drug Advisory Committee (ODAC) meeting in May, panelists concluded in a 3-8 vote, that results of the study failed to show the benefits of quizartinib outweigh the risks for this subgroup of patients.
The panel questioned the lack of robust data, and the large proportion of randomly assigned, untreated patients. The committee also expressed concern over the risk and the modest survival results.
Quizartinib is a small molecule FMS-like tyrosine kinase-3-internal tandem duplication inhibitor that was submitted for approval based on the findings from the phase III QuANTUM-R study. Results from the study showed quizartinib reduced the risk of death by 24% compared with chemotherapy in patients with FLT3-ITD-positive R/R after first-line treatment with or without hematopoietic stem cell transplantation (HSCT).
Prior to the meeting, the FDA conducted its own efficacy analysis and found that the median overall survival (OS) was 26.9 weeks with quizartinib compared with 20.4 weeks with chemotherapy.
In the briefing document, the FDA explained how concerns were raised about the generalizability and credibility of the data.
The FDA is scheduled to make a final decision by the 25th August 2019.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox